Allan-Herndon-Dudley syndrome

Allan-Herndon-Dudley syndrome (AHDS), also known as MCT8 (monocarboxylate transporter 8) deficiency or MCT8-specific thyroid hormone cell-membrane transporter deficiency, is a rare X-linked genetic disorder caused by mutations in the SLC16A2 gene (formerly known as MCT8). This gene encodes a thyroid hormone transporter that is critical for the uptake of triiodothyronine (T3) into neurons and other cells. The condition primarily affects the nervous system and results in severe intellectual disability, impaired speech development, and significant motor dysfunction including hypotonia in infancy that often evolves into spastic paraplegia or a mixed pattern of spasticity and dystonia. Affected individuals are almost exclusively male, though carrier females may occasionally show mild features. The hallmark biochemical finding in AHDS is an abnormal thyroid hormone profile characterized by elevated serum T3 levels, low to low-normal thyroxine (T4) levels, and normal to mildly elevated thyroid-stimulating hormone (TSH). This distinctive pattern of thyroid hormone abnormalities is a key diagnostic clue. Neurologically, affected boys typically present in infancy with severe global developmental delay, inability to sit or walk independently, absent or very limited speech, and progressive movement abnormalities. Many patients also experience feeding difficulties, failure to thrive, reduced muscle mass, and are at risk for underweight status. Seizures may occur in some individuals. Currently, there is no curative treatment for Allan-Herndon-Dudley syndrome. Management is primarily supportive and multidisciplinary, involving physical therapy, occupational therapy, speech therapy, nutritional support, and management of spasticity and seizures when present. The thyroid hormone analog tiratricol (TRIAC, or 3,3',5-triiodothyroacetic acid) has shown promise in clinical trials and is being used in some centers to address the peripheral thyrotoxicosis caused by elevated T3 levels, potentially improving body weight and reducing the risk of cardiac complications associated with excess T3. However, TRIAC has not demonstrated significant improvement in neurological outcomes, particularly when initiated after the critical window of early brain development. Research into earlier intervention and novel therapeutic approaches is ongoing.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Allan-Herndon-Dudley syndrome